Type 2 Diabetes Therapies: A STEPS Approach

Joshua Steinberg, MD, United Health Services Wilson Family Medicine Residency, Johnson City, New York
Lyndsay Carlson, PharmD, BCACP, United Health Services, Johnson City, New York

Only a few years ago, lifestyle modification, sulfonylureas, metformin, and insulin were the only treatment options for type 2 diabetes mellitus. Now, family physicians have approximately 40 medications in 10 categories to manage hyperglycemia in patients with type 2 diabetes. However, the availability of so many choices makes therapeutic decisions more complex. Although all 40 medications will improve blood glucose levels, that is not sufficient. As family physicians, we seek to treat the whole person, not just blood glucose levels, insulin resistance, and islet cell dysfunction. Our patients with diabetes depend on us to help reduce their long-term risk of myocardial infarction, stroke, amputation, dialysis, and premature mortality.

Several recent large randomized controlled trials have significantly improved our knowledge about the impact of diabetes medications on patient-oriented outcomes. After the thiazolidinedione (TZD) rosiglitazone (Avandia) was found to increase the risk of myocardial infarction, the U.S. Food and Drug Administration required newly approved diabetes drugs to undergo rigorous postmarketing studies of long-term cardiovascular harm. Studies evaluating harms, such as major cardiovascular events and cardiovascular mortality, also have the potential to show us which agents confer long-term benefits for those outcomes. The results of these studies can be used to make better choices for our patients with type 2 diabetes.

A concise and organized way to evaluate pharmacotherapy options for diabetes is to use the five patient-oriented STEPS criteria: safety, tolerability, effectiveness, price, and simplicity. Table 1 presents the STEPS approach for each category of diabetes medication. It permits side-by-side comparisons of the pros and cons, and reveals some insights for clinical decision making.

The American Diabetes Association recommends the biguanide metformin (Glucophage) as first-line pharmacotherapy for type 2 diabetes. The STEPS criteria show why: it is safe and fairly well-tolerated, has excellent long-term effectiveness on patient-oriented outcomes, is moderately priced, and has a simple dosing regimen. No other diabetes medication excels in the STEPS criteria as well as metformin. However, most patients with type 2 diabetes require more than one medication. The STEPS approach can help us choose subsequent medications if metformin does not provide adequate glycemic control for our patients.

Focusing first on effectiveness, the table shows evidence of improved patient-oriented outcomes from glucagon-like peptide-1 (GLP-1) receptor agonists and sodium glucose cotransporter-2 (SGLT-2) inhibitors in patients who are at high cardiovascular risk or have known cardiovascular disease. Such improvements are likely to be significantly more modest in patients who are not at high cardiovascular risk. No long-term improvement in patient-oriented outcomes has been demonstrated for the dipeptidyl-peptidase-4 (DPP-4) inhibitors or for the amylin analogue pramlintide (Symlin). The high prices and lack of favorable long-term outcomes leave the use of agents such as sitagliptin (Januvia) and pramlintide hard to justify. The alpha-glucosidase inhibitor acarbose (Precose) has evidence to support improved patient-oriented outcomes, and as with metformin, its price is quite low.

Focusing next on price, the table shows that metformin and, to a lesser extent, acarbose have evidence of a favorable effect on long-term outcomes and are relatively inexpensive. Likewise, inexpensive generic pioglitazone (Actos) is an option with a mix of potential benefits and harms. Sulfonylureas and older insulins are also inexpensive, and although there is no evidence from randomized trials of long-term patient-oriented benefits, there is also no evidence of long-term end-organ harm.

Focusing next on safety, the table shows that several agents are concerning because they increase hypoglycemia risk (e.g., sulfonylureas, insulins, meglitinides, pramlintide) or require monitoring, dose adjustments, or discontinuation in patients with chronic kidney disease (e.g., metformin, acarbose).

Focusing last on simplicity, the table shows that several agents may be challenging for some patients because of the need for frequent or complicated dosing or injections. Poor memory, eyesight, or health literacy may make such a challenging regimen a poor option for some patients.

Although agents within a drug category are more similar than different, a STEPS table comparing each insulin would highlight differences in safety, price, and simplicity. A table comparing each GLP-1 receptor agonist would show that only some (liraglutide [Victoza], semaglutide [Ozempic],...
TABLE 1

Type 2 Diabetes Therapies: A STEPS Approach

<table>
<thead>
<tr>
<th>Drug class</th>
<th>STEPS component</th>
<th>Tolerability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biguanides (e.g., Glucophage)</td>
<td>History of lactic acidosis, but Cochrane review of 347 studies</td>
<td>GI effects (e.g., diarrhea, nausea, vomiting) in &lt; 10% of patients; dis-</td>
</tr>
<tr>
<td></td>
<td>found no cases in 70,490 patient-years, with lactate levels similar</td>
<td>contination rate is &lt; 1%</td>
</tr>
<tr>
<td></td>
<td>between patients receiving metformin (Glucophage) and a control</td>
<td></td>
</tr>
<tr>
<td></td>
<td>group. Should not be used in patients with estimated GFR &lt; 30 mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>per minute per 1.73 m²; use caution in patients with estimated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GFR of 30 to 45 mL per minute per 1.73 m²; Long-term use may</td>
<td></td>
</tr>
<tr>
<td></td>
<td>be associated with vitamin B12 deficiency.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Safe in patients with stable CHF.</td>
<td></td>
</tr>
<tr>
<td>Sulfonylureas (e.g., Glucotrol,</td>
<td>Hypoglycemia</td>
<td>Weight gain¹⁵</td>
</tr>
<tr>
<td>Amaryl)</td>
<td>Hemolytic anemia in patients with glucose-6-phosphate dehydro-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>genase deficiency.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>First generation (chlorpropamide, tolbutamide): systematic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>review shows increased CV mortality (N = 553; RR = 2.63).</td>
<td></td>
</tr>
<tr>
<td>Insulins (e.g., Lantus,</td>
<td>Hypoglycemia, worse with intensive or complicated regimens</td>
<td>Injection, lipodystrophy, weight gain</td>
</tr>
<tr>
<td>Humalog)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TZDs (e.g., Actos, Avandia)</td>
<td>Pioglitazone (Actos): CHF, serious fracture,¹³ bladder cancer</td>
<td>Edema</td>
</tr>
<tr>
<td></td>
<td>(rare)¹⁴</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rosiglitazone (Avandia): CHF, MI¹³</td>
<td></td>
</tr>
<tr>
<td>Alpha-glucosidase inhibitors</td>
<td>Should not be used in patients with cirrhosis or chronic kidney</td>
<td>Severe GI effects (e.g., bloating, diarrhea, flatulence) in ≥ 50% of</td>
</tr>
<tr>
<td>(e.g., Precose)</td>
<td>disease (serum creatinine &gt; 2.0 mg per dL [177 μmol per L])</td>
<td>patients; variable but high discontinue-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ntion rates¹⁵</td>
</tr>
</tbody>
</table>

CHD = coronary heart disease; CHF = congestive heart failure; CV = cardiovascular; DPP-4 = dipeptidyl-peptidase-4; GFR = glomerular filtration rate; GI = gastrointestinal; GLP-1 = glucagon-like peptide-1; MI = myocardial infarction; NA = not available; NNH = number needed to harm; NNT = number needed to treat; RR = relative risk; SGLT-2 = sodium glucose cotransporter-2; STEPS = simplicity, tolerability, effectiveness, price, simplicity; TZDs = thiazolidinediones.

—Based on patient-oriented evidence from randomized controlled trials.
†—Estimated retail price for one month of therapy unless otherwise noted, based on prices obtained from http://www.goodrx.com (accessed January 22, 2019). Generic price listed first; brand name price in parentheses.
§—Although composite outcome improved, no improvement was noted for any individual outcome.
**Type 2 Diabetes Therapies: A STEPS Approach**

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Estimated Retail Price for One Month of Therapy Unless Otherwise Noted, Based on Prices Obtained from Patient-Oriented Sources</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biguanides (e.g., Metformin)</strong></td>
<td>Based on prices obtained from patient-oriented sources.</td>
<td></td>
</tr>
<tr>
<td><strong>Sulfonylureas (e.g., Glipizide)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Avandia (rosiglitazone)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Actos (pioglitazone)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Insulins (e.g., Humalog)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Acarbose (Precose)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other GLP-1Agons</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>DPP-4Inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TZDs (e.g., Actos, Avandia)</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Outcomes:**

- **Benefit:**
  - In 1,704 overweight patients newly diagnosed with diabetes mellitus, metformin improved rates of all-cause mortality (15.5 vs. 20.6 per 1,000 patient-years; NNT = 14), MI (11 vs. 18 per 1,000 patient-years; NNT = 14), microvascular complications (6.7 vs. 9.2 per 1,000 patient-years; NNT = 40), and any diabetes-related end point (29.8 vs. 43.3 per 1,000 patient-years; NNT = 7)\(^7\)

- **Neutral:**
  - First generation: harm
  - Second generation (glipizide [Glucotrol], glyburide): neutral
  - Third generation (glimepiride [Amaryl]): unknown

- **Neutral: Long-term outcomes data**\(^9\)

- **Neutral (when known):**
  - Glargine (Lantus): when used to normalize fasting glucose levels in 12,537 patients with diabetes or prediabetes for 6.2 years, mortality, CV events, and cancers neither increased nor decreased\(^12\)
  - No long-term outcome studies for other insulins or insulin regimens

- **Mixed:**
  - Pioglitazone: in 5,238 patients treated for 9.5 years, no difference in primary CV outcome (CV events plus CV interventions); improved composite secondary CV outcome\(^6\) of all-cause mortality, nonfatal MI, and nonfatal stroke (11.6% vs. 13.6%; NNT = 49); and increased CHF (10.8% vs. 7.5%; NNH = 31) and CHF hospitalizations (5.7% vs. 4.1%; NNH = 61)\(^16\)
  - Rosiglitazone: systematic review of 56 trials (N = 35,531) showed no difference in all-cause mortality and CV mortality, but worse MI odds (odds ratio = 1.28 to 1.38)\(^15\)

**Outcomes:**

- **Benefit (when known):**
  - Acarbose (Precose): systematic review of seven trials not limited to monotherapy (N = 2,180) showed reduced MI risk (RR = 0.36) and reduced risk of any CV event (RR = 0.65)\(^18\)
  - All alpha-glucosidase inhibitors: systematic review of 41 monotherapy trials (N = 8,130) showed no mortality or diabetic end point benefit\(^19\)
  - Acarbose: in 1,429 patients with prediabetes, reduced CV events (2.2% vs. 4.7%; NNT = 41) and MI (0.3% vs. 2.8%; NN T = 41) over 3.2 years\(^20\)
  - Acarbose: in 6,522 patients with CHD and prediabetes, no benefit or harm for mortality, individual, or combined CV outcomes over five years\(^21\)

**Price**

- 1,000 mg twice daily:
  - $5 ($130)
  - Extended-release, four 500-mg tablets once daily: $10 ($130)
  - Extended-release, two 1,000-mg tablets once daily: $730 ($6,650)

**Simplicity**

- Twice-daily oral dosing (once daily for extended-release formulation)

- Glipizide: $5 ($50 to $100, depending on dosage)
- Glyburide: $5 (NA)
- Glimeperide: $5 ($80 to $250, depending on dosage)

- Isophane (NPH): NA ($100 per 10-mL vial)
- Glargine: NA ($190 per 10-mL vial)
- Lispro (Humalog): NA ($180 per 10-mL vial)
- Preloaded pens more expensive

- Once- or twice-daily oral dosing (depending on dosage; once daily for extended-release formulation)

- Pioglitazone: $10 ($600)
- Rosiglitazone: NA ($180)

- Oral dosing before meals (three times daily)

---

\(^*\) Estimated retail price for one month of therapy unless otherwise noted, based on prices obtained from patient-oriented sources.

\(^†\) TZDs = thiazolidinediones; RR = relative risk; GI = gastrointestinal; CHD = coronary heart disease; CHF = congestive heart failure; CV = cardiovascular; NNH = number needed to treat; NNT = number needed to treat; STEPS = simplicity, tolerability, effectiveness, price, simplicity.

---

**Continues**
### TABLE 1 (continued)

#### Type 2 Diabetes Therapies: A STEPS Approach

<table>
<thead>
<tr>
<th>Drug class</th>
<th>STEPS component</th>
<th>Safety</th>
<th>Tolerability</th>
</tr>
</thead>
</table>
| GLP-1 receptor agonists (e.g., Victoza, Ozempic) |                                                                              | Galstones\(^{22}\)  
Occurrence < 1%; acute kidney injury, angioedema, pancreatitis (insufficient data to indicate causal relationship; 16 cases among 14,562 patients in randomized controlled trials)\(^{23}\) | Headache, diarrhea, nausea, weight loss\(^{24}\)          |
| DPP-4 inhibitors (e.g., Januvia, Onglyza) |                                                                              | Pancreatitis (insufficient data to indicate causal relationship), hypoglycemia, slightly higher rates of CHF\(^{28}\) | Rare severe arthralgias                                |
| Meglitinides (e.g., Prandin, Starlix)  |                                                                              | Hypoglycemia, especially with concurrent use of insulin or sulfonylureas (meglitinides are also insulin secretagogues)  
Slight increase in serum uric acid levels | Gl effects in < 10% of patients (e.g., bloating, constipation, cramps, diarrhea, flatulence), dizziness\(^{12}\) |
| Amylin analogue (i.e., Symlin)       |                                                                              | Serious hypoglycemia risk (U.S. Food and Drug Administration boxed warning; preemptive insulin dosage decreases warranted)\(^{24}\)  
Should not be used in patients with gastroparesis (slows gastric emptying) | Nausea (slows gastric emptying)                          |
| SGLT-2 inhibitors (e.g., Jardiance, Invokana) |                                                                              | Hypotension of osmotic diuresis, hyperkalemia in patients with chronic kidney disease, diabetic ketoacidosis, urosepsis, decreased bone mineral density, acute kidney injury (rare)  
Canagliflozin (Invokana) taken for 3.6 years increases the risk of fracture (NNH = 79), amputation (NNH = 96), genital infections in men (NNH = 11), and yeast vaginitis in women (NNH = 5)\(^{25}\) | Slightly more urinary tract infections, many more genital infections |

CHD = coronary heart disease; CHF = congestive heart failure; CV = cardiovascular; DPP-4 = dipeptidyl-peptidase-4; GFR = glomerular filtration rate; GI = gastrointestinal; GLP-1 = glucagon-like peptide-1; MI = myocardial infarction; NA = not available; NNH = number needed to harm; NNT = number needed to treat; RR = relative risk; SGLT-2 = sodium glucose cotransporter-2; STEPS = simplicity, tolerability, effectiveness, price, simplicity; TZDs = thiazolidinediones.

\(^{*}\)—Based on patient-oriented evidence from randomized controlled trials.

\(^{†}\)—Estimated retail price for one month of therapy unless otherwise noted, based on prices obtained from http://www.goodrx.com (accessed January 22, 2019). Generic price listed first; brand name price in parentheses.

\(^{§}\)—Although composite outcome improved, no improvement was noted for any individual outcome.

Information from references 4 through 37.
### Table 1: Type 2 Diabetes Therapies: A STEPS Approach

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Medication</th>
<th>Price†</th>
<th>Simplicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPP-4 inhibitors</td>
<td>Sitagliptin (Januvia)</td>
<td>$90 ($450)</td>
<td>Once-daily oral dosing</td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td>Liraglutide (Victoza)</td>
<td>NA ($920)</td>
<td>Subcutaneous injection twice daily, once daily, or once weekly</td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td>Exenatide weekly</td>
<td>NA ($700)</td>
<td></td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td>Exenatide twice daily</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td>Saxagliptin</td>
<td>NA ($410)</td>
<td></td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td>Sitagliptin</td>
<td>NA ($450)</td>
<td></td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td>Alogliptin</td>
<td>NA ($90)</td>
<td></td>
</tr>
<tr>
<td>SGLT-2 inhibitors</td>
<td>Empagliflozin (Jardiance)</td>
<td>$500 ($480)</td>
<td></td>
</tr>
<tr>
<td>SGLT-2 inhibitors</td>
<td>Canagliflozin</td>
<td>$480 ($500)</td>
<td></td>
</tr>
<tr>
<td>SGLT-2 inhibitors</td>
<td>Dapagliflozin (Farxiga)</td>
<td>$490 ($490)</td>
<td></td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>Nateglinide (Starlix)</td>
<td>$500 ($340)</td>
<td></td>
</tr>
<tr>
<td>Glucagon-like peptide-1 inhibitors</td>
<td>Pramlintide (Symlin)</td>
<td>$1,100 ($1,100)</td>
<td></td>
</tr>
</tbody>
</table>

### Outcomes:

- **Effectiveness**:
  - Liraglutide: benefit (some agents)
  - Exenatide: benefit (when known)
  - Saxagliptin: mixed
  - Sitagliptin: neutral (when known)
  - Empagliflozin: mixed
  - Canagliflozin: mixed
  - Pramlintide: unknown

- **Price**:
  - Liraglutide: NA ($920)
  - Exenatide weekly: NA ($700)
  - Exenatide twice daily: NA ($750)
  - Saxagliptin: NA ($410)
  - Sitagliptin: NA ($450)
  - Alogliptin: NA ($90)
  - Empagliflozin: NA ($480)
  - Canagliflozin: NA ($500)

- **Simplicity**:
  - Once-daily oral dosing
  - Oral dosing before meals (three times daily)
  - Subcutaneous injection before meals (three times daily)
  - Always used with insulin, which necessitates numerous injections

### Outcomes:

- **Neutral (unknown)**
  - Liraglutide: in 9,340 patients with diabetes and high CV risk treated for 3.8 years, improved all-cause mortality (8.2% vs. 9.6%; NNT = 71), CV mortality (4.7% vs. 6.0%; NNT = 77), and CV events (13.0% vs. 14.9%; NNT = 53)\(^{22}\)
  - Semaglutide (Ozempic): in 3,297 patients with diabetes treated for 2.1 years, improved CV events (6.6% vs. 8.9%; NNT = 43), worsened retinal complications (RR = 1.76), and no difference in all-cause or CV mortality\(^{23}\)
  - Exenatide weekly (Bydureon): in 14,752 patients with diabetes and high CV risk treated for 3.2 years, improved all-cause mortality (6.9% vs. 7.9%; NNT = 100); other individual and combined CV outcomes narrowly missed statistical significance for improvement\(^{26}\)
  - Lixisenatide (Adlyxin): in 6,068 patients with diabetes and CHD treated for 2.1 years, no benefit or harm\(^{27}\)
  - All agents in this class independently produce direct weight loss

- **Benefit (some agents)**
  - Liraglutide (Victoza): in 9,340 patients with diabetes and high CV risk treated for 3.8 years, improved all-cause mortality (8.2% vs. 9.6%; NNT = 71), CV mortality (4.7% vs. 6.0%; NNT = 77), and CV events (13.0% vs. 14.9%; NNT = 53)\(^{22}\)
  - Semaglutide (Ozempic): in 3,297 patients with diabetes treated for 2.1 years, improved CV events (6.6% vs. 8.9%; NNT = 43), worsened retinal complications (RR = 1.76), and no difference in all-cause or CV mortality\(^{23}\)
  - Exenatide weekly (Bydureon): in 14,752 patients with diabetes and high CV risk treated for 3.2 years, improved all-cause mortality (6.9% vs. 7.9%; NNT = 100); other individual and combined CV outcomes narrowly missed statistical significance for improvement\(^{26}\)
  - Lixisenatide (Adlyxin): in 6,068 patients with diabetes and CHD treated for 2.1 years, no benefit or harm\(^{27}\)
  - All agents in this class independently produce direct weight loss

### Outcomes:

- **Neutral (when known)**
  - Sitagliptin (Januvia): in 14,671 patients with diabetes treated for 3 years, no CV or mortality benefit or harm\(^{29}\)

- **Neutral (when known)**
  - Saxagliptin (Onglyza) and alogliptin (Nesina): short randomized controlled trials showed no CV benefit or harm\(^{29},^{31}\)

- **Neutral (when known)**
  - Nateglinide (Starlix): in 9,306 patients with prediabetes and high CV risk treated for 5 years, no increase or decrease in mortality, combined CV outcomes, or individual CV outcomes\(^{13}\)

- **Unknown (unknown)**
  - No studies with patient-oriented outcomes

### Outcomes:

- **Unknown (unknown)**
  - No studies with patient-oriented outcomes

### Notes:

- TZDs = thiazolidinediones.
- *—Based on number needed to treat; RR = relative risk; GI = gastrointestinal; CCC = cancer; MI = myocardial infarction; NA = not available; NNH = number needed to harm; NNT = number needed to treat.
- DPP-4 = dipeptidyl-peptidase 4.
- GLP-1 = glucagon-like peptide-1.
- SGLT-2 = sodium glucose co-transporter 2.
- GI = gastrointestinal.
- CHF = congestive heart failure.
- MI = myocardial infarction.
- NNT = number needed to treat.
- NNH = number needed to harm.
- STEPS = simplicity, tolerability, effectiveness, price, simplicity.
exenatide) have proven cardiovascular benefit, whereas others have no evidence of benefit and still others have outcome studies that have not been completed.

Major guidelines are increasingly aligned with a STEPS approach to pharmacotherapy for type 2 diabetes. Although it has traditionally focused on disease-oriented outcomes, the American Diabetes Association was more patient-oriented in 2018, strongly recommending metformin as first-line therapy, with additional agents added after consideration of hypoglycemia risk, comorbidities, potential adverse effects, effectiveness, price, and delivery method. The American Academy of Family Physicians--endorsed 2017 guideline on pharmacotherapy for type 2 diabetes from the American College of Physicians shares an emphasis on safety, tolerability, effectiveness, and price when making initial choices about monotherapy and combination therapy, while focusing on improving patient-oriented outcomes amidst a dearth of evidence regarding specific combinations of hypoglycemic drugs. Likewise, the 2017 guideline from the Department of Veterans Affairs and Department of Defense also recommends metformin first, then additional agents according to evidence of effectiveness and consideration of safety, adverse effects, cost, and comorbidities. All of these guidelines are consistent with an evidence-based STEPS approach.

Data Sources: Essential Evidence Plus and the Cochrane database were searched using the keywords type 2 diabetes and medication therapy. Trials and systematic reviews referenced in the 2017 American Diabetes Association guideline and package inserts of newer medications, and selected relevant references were used. Search dates: August 2017 to October 2018.

The Authors

JOSHUA STEINBERG, MD, is a faculty member at United Health Services Wilson Family Medicine Residency, Johnson City, NY, and a clinical assistant professor of family medicine at State University of New York Upstate Medical University, Binghamton Clinical Campus.

LYNDSAY CARLSON, PharmD, BCACP, is an ambulatory care clinical pharmacy specialist at United Health Services, Johnson City, NY.

Address correspondence to Joshua Steinberg, MD, United Health Services Wilson Family Medicine Residency, 507 Main St., Johnson City, NY 13790 (e-mail: jds91md@gmail.com). Reprints are not available from the authors.

References


